EpiBone, Inc. approved by FDA to begin first human trials of EB-CMF Phase 1/2
-
Last Update: 2020-06-03
-
Source: Internet
-
Author: User
Search more information of high quality chemicals, good prices and reliable suppliers, visit
www.echemi.com
EB-CMF is a living, anatomically correct bone graft made from the patient's own fat stem cellsThis avoids the need to get bones from the patient's body, reduces pain, surgery, and hospital time, while accurately matching defectsPhase 1/2 clinical study will directly evaluate the application of EB-CMF products in patients with continuing jaw branch defects that need to be reconstructedIn addition to the main safety of EB-CMF, this study is designed to demonstrate the effectiveness of EB-CMF in bone reconstruction and integration with natural tissuesThe company plans to recruit six patients to participate in the studyThe company hopes the study will help explore potential indications from other facial reconstruction surgeries that require bone transplants, as well as research on knee cartilage replacement and other parts of the body.
This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only.
This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of
the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed
description of the concern or complaint, to
service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content
will be removed immediately.
